Melody Cobleigh to Disease-Free Survival
This is a "connection" page, showing publications Melody Cobleigh has written about Disease-Free Survival.
Connection Strength
0.254
-
Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer. Ann Oncol. 2016 06; 27(6):1029-1034.
Score: 0.130
-
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999 Sep; 17(9):2639-48.
Score: 0.041
-
Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer. Clin Cancer Res. 2017 Oct 01; 23(19):5687-5695.
Score: 0.036
-
Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. Clin Cancer Res. 2011 Jan 15; 17(2):372-81.
Score: 0.023
-
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol. 2002 Aug 01; 20(15):3317-27.
Score: 0.013
-
First-line Herceptin monotherapy in metastatic breast cancer. Oncology. 2001; 61 Suppl 2:37-42.
Score: 0.011